Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ: RIGL · IEX Real-Time Price · USD
1.49
-0.03 (-1.97%)
At close: Aug 8, 2022 4:00 PM
1.47
-0.02 (-1.34%)
Pre-market: Aug 9, 2022 6:58 AM EDT
-1.97%
Market Cap 257.53M
Revenue (ttm) 88.51M
Net Income (ttm) -84.53M
Shares Out 172.84M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,482,491
Open 1.51
Previous Close 1.52
Day's Range 1.40 - 1.54
52-Week Range 0.64 - 4.24
Beta 1.63
Analysts Buy
Price Target 2.19 (+47.0%)
Earnings Date Aug 2, 2022

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treat... [Read more...]

Industry Biotechnology
IPO Date Nov 29, 2000
CEO Raul Rodriguez
Employees 165
Stock Exchange NASDAQ
Ticker Symbol RIGL
Full Company Profile

Financial Performance

In 2021, RIGL's revenue was $149.24 million, an increase of 37.39% compared to the previous year's $108.62 million. Losses were -$17.91 million, -39.77% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is 2.19, which is an increase of 46.98% from the latest price.

Price Target
$2.19
(46.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

Second quarter TAVALISSE® net product sales of $18.6 million and total revenues of $29.8 million Expanded Rigel's hematology-oncology portfolio by entering into an exclusive license agreement with Forma...

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhib...

Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid ...

Other symbols: FMTX

Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , July 26, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2022 financial results after market close on...

Biotech Penny Stocks Investing Guide

What to know about trading biotech stocks in 2022 The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: EVOKZOM

Best Penny Stocks to Watch as the Market Crashes Again

Here are three penny stocks to add to your watchlist right now The post Best Penny Stocks to Watch as the Market Crashes Again appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other symbols: ACORKGC

Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks

Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.

Why Rigel Pharmaceuticals Shares Are Falling Today

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance ...

Rigel Pharmaceuticals' Fostamatinib Flunks In Late-Stage Rare Blood Disorder Trial

Rigel Pharmaceuticals Inc (NASDAQ: RIGL) shares are falling on disappointing data from the FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA).  wAIHA is an a...

Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune...

Conference call and webcast to be held today at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize F...

MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and s...

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports First Quarter 2022 Financial Results and Provides Business Update

First quarter TAVALISSE® net product sales of $16.2 million and total revenues of $16.7 million T opline data from FORWARD study, a pivotal, Phase 3 clinical trial of fostamatinib in warm autoimmune hem...

Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update

– Key Opinion Leader and FORWARD trial investigator, Caroline Piatek, M.D., to join Rigel management to share experience and insight treating patients with wAIHA – SOUTH SAN FRANCISCO, Calif.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , April 8, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported the grant of stock options to purchase an aggregate of 626,000 shares of common stoc...

How to Trade Penny Stocks in April 2022 and 3 to Watch

Here's what you need to know about trading penny stocks in April The post How to Trade Penny Stocks in April 2022 and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Other symbols: CELZEOSEIBIO

Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Au...

SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in the American Journal of Hematology from the open label, m...

Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 0% and 3.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2021, inclu...

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business...

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after mark...

Rigel to Present at the J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is schedul...

Rigel Pharmaceuticals Provides Business Update

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary 2021 full-year total revenue, the status of t...

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd.

Rigel Appoints Kamil Ali-Jackson to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors.

Rigel Sharpens Focus on Its Advanced Portfolio Opportunities

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced plans to exit early-stage research and focus resources on its mid to late-stage devel...